Abstract: A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose oil. Preferably, the composition includes a fragrance, such as peach oil and marjoram and 1% to 10% by weight of vitamins A, C, D, E and K.

Abstract: The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation.

Abstract: The present invention deals with a multiparticulate tablet, which disintegrates in the mouth containing: i) a proton pomp inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as for instance a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO3 and/or Mg(OH)2 and/or Al(OH)3; and, iii) a mixture of excipients comprising at least one disintegrating agent, one diluent agent, a lubricant, and optionally a swelling agent, a permeabilising agent, sweeteners, flavourings and colours. Furthermore, the present invention is directed to processes for the manufacture of the tablet and its use in the treatment of gastrointestinal disorders.

Abstract: The present invention relates to compositions comprising an effective amount of a Panaxytriol Compound and a tubulin-binding drug, methods for treating or preventing cancer or a neurotrophic disorder comprising administering to a subject in need thereof an effective amount of a Panaxytriol Compound and a tubulin-binding drug, and methods for making a Panaxytriol Compound.

Abstract: A method for imparting a teeth-desensitising effect to a food, cosmetic or pharmaceutical which comprises combining said food, cosmetic or pharmaceutical with a teeth-desensitising effective amount of a polyol.

Abstract: Glycerol-containing solutions are useful for improving both the metabolic and hydration state of fasting individuals. The same solutions can be utilized in persons facing situations where urination is impossible or inconvenient.

Abstract: What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.

Abstract: A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that can be used to screen libraries of compounds for individual compounds that are predicted to have high binding affinities for the target protein.

Abstract: Processes for the hydrogenolysis of glycerol, as well as products produced therefrom are disclosed.

Abstract: Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intralumenal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

Abstract: The present invention features a process for making a tablet by (i) compacting a powder blend in a die to form a tablet shape, wherein the powder blend contains a pharmaceutically active agent and a meltable binder and (ii) applying radiofrequency energy to the tablet shape for a sufficient period of time to soften or melt the binder within said tablet shape to form the tablet.

Abstract: The invention relates to an emollient composition for topical use that comprises a combination of glycerol, Vaseline and liquid paraffin as an active principle, in the form of an oil-in-water or water-in-oil emulsion. The invention also relates to: the use thereof for preparing a drug for treating dry skin conditions associated with certain dermatoses such as atopic dermatitis, ichthyosis conditions and psoriasis; the use thereof for preparing a drug for treating small superficial burns; and the use thereof for preparing a drug for preventing and/or treating and/or reducing the frequency and intensity of eczema attacks observed in patients suffering from atopic dermatitis.

Abstract: The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, aneurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents.

Abstract: The invention relates to a composition for topical use that comprises a combination of glycerol, Vaseline and liquid paraffin as an active principle, in the form of an oil-in-water or water-in-oil emulsion, said composition being used in the prevention of atopic dermatitis.

Abstract: A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.

Abstract: An edible product for oral hygiene of a pet, the product being chewable by the pet to remove plaque, tartar and stain from the teeth of the pet and to reduce breath odor of the pet. The dental hygiene product includes a body formed of a first set of constituent components and a second set of constituent components, the first set of constituent components including abrasive components and one or more breath freshening components, the combination when chewed by the pet effecting the removal of plaque, tartar and stain and the inhibition of breath odor, the second set of constituent components including an abrasive component and one or more active components, the abrasive component when chewed by the pet effecting the removal of plaque, tartar and stain from the teeth of the pet, the one or more active components being characterized by the active components disrupting growth of bacteria in the pet's mouth thereby inhibiting plaque and tartar formation and breath odor from a bacterial source.

Abstract: The invention relates to the use of a compound comprising D-mannoheptulose and/or perseitol for producing a drug for treating and/or preventing diseases related to the modification of an innate and/or acquired immunity by increasing the production of antimicrobial peptides, preferably hBD-2 without inducing inflammatory reactions, irritation or intolerance. Said compound can also comprise a peptidic avocado extract and/or a peptidic lupin extract.

Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersonmia; endozepine related recurrent stupor; and amphetamine resistant hypersonmia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

Abstract: An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25 wt % of an oil-in-water nonionic emulsifier, wherein the emulsifier is selected from the following group of: hydrophilic nonionic surfactants with polyoxyethylene chains as hydrophilic groups, polyglycerol fatty acid esters, polyglycerol fatty alcohol ethers, sucrose fatty acid esters, and hydrocarbyl polyglycosides. The oil-in-water microemulsion carries a large amount of oil. In addition, the use of an oil/fat containing polyoxypropylene chains is disclosed for increasing the amount of oil carried in an oil-in-water microemulsion.

Abstract: The invention relates to an aqueous suspension formulation comprising a coarsely particulate carbon adsorbent which is suitable for binding and eliminating harmful substances from the gastrointestinal tract, and a water-soluble or water-dispersible structure-forming agent and a humectant.

Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.

Abstract: A method of reducing a vasodilatory response comprising administering to an individual in need of such treatment an effective amount of a guanylate cyclase pathway inhibitor selected from the group consisting of methylene blue, ODQ, LY83583 and a protein kinase G inhibitor or an H2O2 reducing agent selected from the group consisting of Aspergillus niger catalase and hydroxyl scavengers, hydroquinone and mannitol.

Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: The invention relates to a composition comprising a oil-soluble high carbon polar modified polymer, a sugar silicone surfactant and a hyperbranched polyol.

Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.

Abstract: The present disclosure generally relates to a multi-component biocide composition comprising a borate component in combination with an azole component to both inhibit mold fungi, decay fungi, such as brown-rot fungi and white-rot fungi, and to resist insect infestation.

Abstract: The present invention relates to a use of 1,2-decanediol for reduction of the sebum concentration of the skin, a cosmetic and/or dermatological formulation for topical application comprising 1,2-decanediol, a method for reduction of the sebum concentration of the skin and a use of 1,2-decanediol and a method for assisting the penetration of one, two, three, four or more active compounds into areas of the skin with increased sebum production.

Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.

Abstract: An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, and the dermal regeneration enhancer of the present invention achieves an excellent suppressive effect to aging of the skin, generation of spots, etc.

Abstract: A gel that includes a fungicide or an anti-bacterial is contained within a single dosage packet that includes a tapered nozzle end and a body. The fungicide or anti-bacterial gel is applied to the hoof of a horse by opening the packet at the tapered nozzle end and squeezing the body. The gel is then spread over the frog and sole of the hoof with a portion of the packet. The gel is heated so that it spreads to recessed areas of the hoof that can contain the bacterial and fungus infections.

Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.

Abstract: A stable, low VOC, low viscosity biocide formulation comprising an effective amount of at least one biocide, and a alkyl poly glycol liquid carrier of formula (I): R—O-(AO)n—H, wherein R is a C1-C3 alkyl; AO is an ethyleneoxide group, a propy-leneoxide group, a butyleneoxide group, or a block or random copolymer of two or more groups selected from an ethyleneoxide group, a propyleneoxide group, and a butyleneoxide group; and n is the average number of repeating AO units and is at least 4.

Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in blood vessels of a patient is provided. The chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive product is administered at sites of the plaques formed in the patient's blood vessels. The chemical composition comprises, for example, one or more of d-limonene, propylene glycol, octanic acid, 2-octane, and glycerine. The chemical composition enables modification of the plaques by altering composition of the plaques. The modification comprises partial dissolution, complete dissolution or elimination of the plaques. The modification makes the plaques amenable to different forms of plaque treatment, for example, balloon angioplasty, stenting, atherectomy, etc. The modified plaques are eliminated from the body of the patient.

Abstract: A bacterial autoinducer, CAI-1, was purified and its structure identified. Methods for synthesis of the autoinducer and its analogues were elucidated. Methods of using the autoinducer or its analogues for treating bacterial pathogenicity and bio film formation are described. Methods for prevention and treatment of cholera are described. Synthetic (S)-3-hydroxytridecan-4-one functions as well as natural CAI-1 in repressing production of the virulence factor toxin co-regulated pilus (TCP). Strategies are described to manipulate bacterial quorum sensing in the clinical arena.

Abstract: This invention is directed to compounds of formula (I), wherein m, formula (II), R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Abstract: Provided herein are powder-free elastomeric articles exhibiting good antimicrobial and anti-blocking properties. Also provided herein are methods for the manufacture of such articles substantially free from antimicrobial interfering materials, as well as packaging means for maintaining antimicrobial efficacy.

Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.

Abstract: A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na+) and calcium (Ca2+) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.

Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.

Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant.

Abstract: The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff formation, as well as to cosmetic and/or dermatological preparations comprising C10-C14-alkane-1,2-diols.

Abstract: Synergistically active mixtures of straight-chain 1,2-alkanediols having 5 to 10 C atoms and their use as skin moisture-regulating compositions are described. Binary and ternary mixtures of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol have proved to be particularly active here. Cosmetic or pharmaceutical formulations and ready-to-use cosmetic or pharmaceutical products comprising particularly synergistically active mixtures of the 1,2-alkanediols mentioned and the use of these formulations and products are furthermore described.

Abstract: A patient in need of nitroglycerin therapy is treated with nitroglycerin and agent that prevents inhibition of or reverses inhibition of mtALDH and/or the generation of reactive oxygen species from mitochondria, e.g., a mitochondrial antioxidant which is not a reducing agent or a dithiol, e.g., ebselen or uric acid. Nitroglycerin dosage can be regulated and inhibiting agent dosage can be regulated and tolerance postponed by monitoring blood level of active mtALDH and dosing in response to determined level of active mtALDH.

Abstract: The present invention relates to a copolymer, which is the reaction product of (a) a first prepolymer, comprising a bioactive moiety and at least one radically polymerizable group, and (b) a second prepolymer which is a polyvinyl alcohol having a weight average molecular weight of at least about 2000 that, based on the number of hydroxy groups of the polyvinyl alcohol, comprises from 0.5 to 80% structural units of formula (I) wherein: R is alkylene having up to 8 carbon atoms, R1 is hydrogen or alkyl having up to seven carbon atoms, and R2 is an olefinically unsaturated, electron-attracting copolymerizable radical.

Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.

Abstract: The present invention relates to specific synergistic active antimicrobial compositions for hygiene disinfectant products like antimicrobial liquid or solid soaps, disinfectant cleansing solutions and disinfectant emulsions for the treatment of skin surface, specifically for the treatment of hand surface and/or for the treatment of technical surfaces like e.g. surgery equipment comprising a mixture comprising or consisting of a) an antimicrobial active amount of 1,2-decanediol of formula 1: and b) an antimicrobial active amount of one or more compounds selected from the group consisting of ethanol, propan-1-ol, propan-2-ol; chlorhexidine digluconate, chloroxylenol, triclosan, triclocarban, benzethonium chloride, methylbenzethonium chloride and benzalkonium chloride.

Abstract: Disclosed is an antimicrobial carbon black dispersion which exhibits excellent dispersant properties and also inhibits microbial contamination when used in consumer products such as cosmetic formulations. Also disclosed are methods for producing and using the antimicrobial carbon black dispersion.

Abstract: The purpose of the present invention is to provide antiseptic disinfectant, and cosmetics and toiletries, medicine or food containing the same, which enhance the antibacterial activity that 1,2-alkanediol originally have against a broad range of strains by compounding 1,2-alkanediol with 5-10 carbons and a certain fragrance component. The present invention relates to an antiseptic disinfectant, and cosmetics and toiletries, medicine or food containing the same, which include 1,2-alkanediol with 5-10 carbons, and one or more materials selected from a group of thymol, eugenol, citronellal, terpinyl acetate, citronellol and ?-pinene.

Abstract: An O/W emulsion which comprises one or more fatty alcohols, one or more glycerol esters of fatty acids and at least 15% by weight, based on the total weight of the emulsion, of at least one moisturizer. Also disclosed is a cosmetic composition which comprises the emulsion.

Abstract: A composition-of-matter comprising a substance usable in producing packaging material and at least one compound selected from the group consisting of ar-turmerone, a sesquiterpene alcohol and a turmeric oleoresin solid residue.